Mateon Therapeutics (OTCMKTS: MATN) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Mateon Therapeutics and VBI Vaccines, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mateon Therapeutics 0 1 3 0 2.75
VBI Vaccines 0 0 3 0 3.00

Mateon Therapeutics currently has a consensus target price of $1.75, indicating a potential upside of 1,066.67%. VBI Vaccines has a consensus target price of $10.50, indicating a potential upside of 138.64%. Given Mateon Therapeutics’ higher possible upside, equities analysts clearly believe Mateon Therapeutics is more favorable than VBI Vaccines.

Institutional and Insider Ownership

20.9% of VBI Vaccines shares are owned by institutional investors. 4.5% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 34.1% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Mateon Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mateon Therapeutics and VBI Vaccines’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mateon Therapeutics N/A N/A -$13.65 million ($0.56) -0.27
VBI Vaccines $550,000.00 510.48 -$23.20 million N/A N/A

Mateon Therapeutics has higher earnings, but lower revenue than VBI Vaccines.

Profitability

This table compares Mateon Therapeutics and VBI Vaccines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mateon Therapeutics N/A -210.82% -175.67%
VBI Vaccines -4,463.06% -49.17% -37.55%

Summary

VBI Vaccines beats Mateon Therapeutics on 7 of the 10 factors compared between the two stocks.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

VBI Vaccines Company Profile

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.